SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (8335)10/16/2000 11:54:34 AM
From: keokalani'nui  Read Replies (1) | Respond to of 9719
 
Corixa has very shrewd deal makers (they bought the RIBI adjuvant for peanuts; they have a gazillion licensing deals; they bought a first generation cancer vaccine to give credence to their story; and now with Bexxar they are going to have the real thing), and they certainly understand how to market a company better than me....for I have never understood its valuation. If this transaction takes them up to a $1.5-$2b capitalization I wouldn't hold it. Just MO.

--Wilder



To: Vector1 who wrote (8335)10/16/2000 3:14:59 PM
From: rkrw  Respond to of 9719
 
I saw the CEO of CRXA speak about a year ago. They showed some amazing slides of psoriasis patients. Nasty cases, completely cleared with their vaccine. My caveat is the trial was done in a third world nation. I always consider this to be a red flag. The psoriasis trial appears to be crxa's most visible program.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News